Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Dietary Cholesterol Absorption Inhibitor [EPC]
Simvastatin is a lipid-lowering medication in the HMG-CoA reductase inhibitor class. It is primarily used to reduce elevated lipid levels and decrease the risk of cardiovascular events such as heart attack and stroke.
Name
Simvastatin
Raw Name
SIMVASTATIN
Category
Dietary Cholesterol Absorption Inhibitor [EPC]
Drug Count
4
Variant Count
195
Last Verified
February 17, 2026
RxCUI
476345, 476349, 476350, 476351, 1245420, 1245430, 1245441, 1245449, 200345, 312961, 312962, 314231, 198211, 104490, 104491, 152923
UNII
EOR26LQQ24, AGG2FN16EV
About Simvastatin
Simvastatin is a lipid-lowering medication in the HMG-CoA reductase inhibitor class. It is primarily used to reduce elevated lipid levels and decrease the risk of cardiovascular events such as heart attack and stroke.
Detailed information about Simvastatin
References used for this content
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Simvastatin.
In clinical terms, simvastatin is a prodrug, meaning it is administered in an inactive lactone form and must be hydrolyzed in the liver to its active beta-hydroxy acid form. Once activated, it works by inhibiting the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. This enzyme is the rate-limiting step in the hepatic production of cholesterol. By reducing the liver's internal production of cholesterol, simvastatin forces the liver to increase the number of LDL (low-density lipoprotein) receptors on the surface of liver cells, which enhances the uptake and breakdown of circulating 'bad' cholesterol from the blood.
Beyond its primary role in lipid management, simvastatin is recognized for its 'pleiotropic' effects. These are secondary benefits that go beyond simple cholesterol lowering, including the improvement of endothelial (blood vessel lining) function, stabilization of atherosclerotic plaques (reducing the risk of rupture), and reduction of systemic inflammation and oxidative stress. These combined actions make it a cornerstone therapy in the primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD).
The therapeutic efficacy of simvastatin is rooted in its highly specific inhibition of HMG-CoA reductase. At the molecular level, the active form of simvastatin mimics the structure of HMG-CoA, the natural substrate for the enzyme. By binding to the active site of the enzyme with much higher affinity than the natural substrate, simvastatin effectively blocks the conversion of HMG-CoA into mevalonate. Mevalonate is a critical precursor not only for cholesterol but also for other important isoprenoids.
When the intracellular concentration of cholesterol in the liver drops due to this inhibition, a regulatory protein called SREBP (Sterol Regulatory Element-Binding Protein) is activated. SREBP moves to the cell nucleus and triggers the expression of the gene for the LDL receptor. The resulting increase in LDL receptors on the hepatocyte (liver cell) membranes allows the liver to efficiently clear LDL-C (low-density lipoprotein cholesterol) and VLDL (very-low-density lipoprotein) remnants from the plasma. This process typically results in a 30% to 50% reduction in LDL-C levels, depending on the dose. Furthermore, simvastatin moderately increases HDL-C ('good' cholesterol) and reduces triglycerides, contributing to a more favorable overall lipid profile.
Understanding the pharmacokinetics of simvastatin is vital for optimizing therapy and avoiding adverse events.
Simvastatin is FDA-approved for several indications related to cardiovascular health:
Simvastatin is primarily available in oral formats to ensure ease of use and consistent dosing:
> Important: Only your healthcare provider can determine if Simvastatin is right for your specific condition. The choice of statin and the specific dose must be individualized based on your cardiovascular risk profile and baseline lipid levels.
The dosage of simvastatin must be individualized according to the patient's baseline LDL-C levels, the goal of therapy, and the patient's response.
Simvastatin is approved for use in children with Heterozygous Familial Hypercholesterolemia (HeFH).
Because simvastatin does not undergo significant renal excretion, modification of dosage should not be necessary for patients with mild to moderate renal insufficiency. However, in patients with severe renal impairment (Creatinine Clearance < 30 mL/min), doses above 10 mg daily should be implemented with extreme caution and close monitoring.
Simvastatin is contraindicated in patients with active liver disease or unexplained, persistent elevations of serum transaminases. In patients with chronic stable liver disease, use must be carefully evaluated by a specialist.
Clinical studies indicate that the maximum LDL-lowering effect is often seen at lower doses in the elderly. Furthermore, patients over age 65 are at a higher risk for statin-induced myopathy. Healthcare providers often start elderly patients at the lower end of the dosing spectrum (e.g., 5 mg or 10 mg).
If you miss a dose, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and return to your regular routine. Never 'double up' on doses to make up for a missed one, as this increases the risk of toxicity.
In the event of an overdose, contact a poison control center or seek emergency medical attention immediately. While specific symptoms of simvastatin overdose are not well-documented in clinical literature, general supportive measures should be taken. Monitoring of liver function and creatine kinase (CK) levels is essential to check for muscle or liver damage.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking the medication without medical guidance, as this may lead to a rapid increase in cholesterol levels and cardiovascular risk.
Most patients tolerate simvastatin well; however, some common side effects may occur, particularly during the first few weeks of treatment:
While rare, some side effects are potentially life-threatening and require immediate intervention:
> Warning: Stop taking Simvastatin and call your doctor immediately if you experience unexplained muscle pain, tenderness, or weakness, especially if accompanied by fever or malaise.
There are currently no FDA black box warnings for simvastatin. However, the FDA has issued several high-level safety communications, particularly regarding the 80 mg dose and the risk of myopathy, which serve as the strongest possible warnings short of a black box. The label contains prominent contraindications against using simvastatin with strong CYP3A4 inhibitors, which is a critical safety parameter.
Report any unusual symptoms or persistent side effects to your healthcare provider immediately. Regular blood tests are often used to monitor for these effects before they become serious.
Simvastatin is a highly effective medication, but it requires careful monitoring to ensure safety. Patients must be aware that the risk of muscle damage (myopathy) increases significantly with higher doses and when taken with certain other medications. It is also vital to maintain a heart-healthy diet while taking this medication, as simvastatin is meant to complement, not replace, lifestyle modifications.
As of 2024, there are no FDA black box warnings for simvastatin. The most critical safety information is found in the 'Contraindications' and 'Warnings and Precautions' sections of the prescribing information, focusing on drug interactions and muscle safety.
Simvastatin, like other statins, can occasionally cause myopathy, manifested as muscle pain, tenderness, or weakness with creatine kinase (CK) levels above ten times the upper limit of normal. The risk is dose-related and is highest with the 80 mg dose. Factors that increase this risk include advanced age (≥65), female gender, uncontrolled hypothyroidism, and renal impairment.
Persistent elevations in serum transaminases (liver enzymes) have occurred in a small percentage of patients. It is recommended that liver function tests be performed before initiating therapy and thereafter when clinically indicated. If AST or ALT levels increase to three times the upper limit of normal and persist, the drug should be discontinued.
Increases in HbA1c and fasting serum glucose levels have been reported with statins. Patients at risk for diabetes should be monitored closely. Additionally, caution should be exercised if simvastatin is co-administered with drugs that may decrease the levels or activity of endogenous steroid hormones (like ketoconazole).
To ensure the safe use of simvastatin, healthcare providers typically order the following tests:
Simvastatin generally does not affect the ability to drive or operate machinery. However, rare side effects like dizziness or blurred vision have been reported. Patients should observe how they react to the medication before engaging in these activities.
Excessive alcohol consumption can increase the risk of liver damage when taking simvastatin. Patients who consume substantial quantities of alcohol or have a history of liver disease should discuss this with their doctor. Moderate alcohol consumption is generally acceptable, but 'binge drinking' should be avoided.
Simvastatin can be stopped without a tapering period; there is no known 'withdrawal syndrome.' However, stopping the medication will result in cholesterol levels returning to their baseline within a few weeks, which increases cardiovascular risk. Never stop taking simvastatin without consulting your physician.
> Important: Discuss all your medical conditions, including any history of liver disease, kidney disease, or thyroid problems, with your healthcare provider before starting Simvastatin.
The following medications are strong CYP3A4 inhibitors and must NEVER be used with simvastatin, as they can cause a massive increase in simvastatin blood levels, leading to life-threatening rhabdomyolysis:
Certain drugs require a strict limit on the dose of simvastatin to prevent toxicity:
Simvastatin does not typically interfere with most common laboratory tests, though it will obviously change lipid panel results. It may cause an increase in serum transaminases (liver enzymes) and creatine kinase (CK), which could be misinterpreted if the clinician is unaware the patient is on a statin.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter drugs like cold medicines or pain relievers.
Simvastatin must NEVER be used in the following circumstances:
These conditions require a careful risk-benefit analysis by a healthcare provider:
Patients who have experienced 'statin-associated muscle symptoms' (SAMS) with other HMG-CoA reductase inhibitors (like atorvastatin or rosuvastatin) may also experience them with simvastatin. However, some patients who cannot tolerate lipophilic statins (like simvastatin) may tolerate hydrophilic ones (like pravastatin) better. This must be managed by a specialist.
> Important: Your healthcare provider will evaluate your complete medical history, including your family history of muscle disorders, before prescribing Simvastatin.
Historically, simvastatin was classified as Pregnancy Category X. In 2021, the FDA requested that the absolute contraindication for statins be removed for all patients, allowing for a more individualized approach. However, for most patients, the risks of taking a statin during pregnancy outweigh the benefits, as the treatment of high cholesterol is rarely urgent during the nine months of gestation. If a patient becomes pregnant while taking simvastatin, they should stop the medication immediately and contact their doctor.
Due to the risk of disrupting the lipid metabolism of the developing infant, breastfeeding is not recommended while taking simvastatin. There are no adequate studies on the presence of simvastatin in human breast milk, but the theoretical risk to the infant's development is significant.
Simvastatin is approved for children aged 10 to 17 years who have Heterozygous Familial Hypercholesterolemia. It has been shown to be effective in lowering LDL-C in this population without affecting growth, development, or sexual maturation. It is not approved for children under 10 years of age.
Patients over the age of 65 are at an increased risk of myopathy when taking simvastatin. In clinical trials, elderly patients showed a higher mean plasma concentration of the drug compared to younger patients. Dose selection should be cautious, usually starting at the low end of the range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and concomitant diseases or other drug therapies.
For patients with mild to moderate renal impairment, no dose adjustment is necessary. For those with severe renal impairment (Creatinine Clearance < 30 mL/min), the starting dose should be 5 mg, and doses above 10 mg should be used only with extreme caution. Simvastatin is not significantly cleared by hemodialysis.
Simvastatin is contraindicated in active liver disease. In patients with stable, chronic liver issues, the drug should be used with caution. There is no specific dosing adjustment based on Child-Pugh classification, but close monitoring of liver enzymes is mandatory.
> Important: Special populations require individualized medical assessment and more frequent follow-up visits to ensure the medication is both safe and effective.
Simvastatin is a specific inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, which is an early and rate-limiting step in the biosynthesis of cholesterol. The drug is a structural analog of the HMG-CoA intermediate. By inhibiting this enzyme, simvastatin reduces the amount of cholesterol produced by liver cells. This lead to an 'upregulation' of LDL receptors on the surface of these cells, which then pull LDL cholesterol out of the bloodstream, effectively lowering circulating levels.
Simvastatin reduces total cholesterol, LDL-C, and VLDL-C. It also produces moderate increases in HDL-C and reduces plasma triglycerides. The therapeutic response is usually evident within two weeks, and the maximum response is typically achieved within four to six weeks. The effects are maintained as long as therapy continues. Upon discontinuation, cholesterol levels return to pre-treatment levels.
| Parameter | Value |
|---|---|
| Bioavailability | < 5% (Extensive first-pass metabolism) |
| Protein Binding | ~95% |
| Half-life | 1.9 hours (Active metabolite) |
| Tmax | 1.3 to 2.4 hours |
| Metabolism | Hepatic (CYP3A4) |
| Excretion | Fecal (60%), Renal (13%) |
Simvastatin is classified as an HMG-CoA Reductase Inhibitor (Statin). It is part of a therapeutic class of lipid-modifying agents. Other drugs in this class include atorvastatin, rosuvastatin, pravastatin, and lovastatin. Compared to other statins, simvastatin is considered of 'moderate intensity' at its standard 20-40 mg doses.
Medications containing this ingredient
Common questions about Simvastatin
Simvastatin is primarily used to lower high levels of 'bad' cholesterol (LDL) and triglycerides in the blood, while slightly increasing 'good' cholesterol (HDL). It belongs to a class of drugs called statins, which work by blocking an enzyme in the liver responsible for cholesterol production. By lowering these fats, simvastatin helps prevent the buildup of plaque in the arteries, a condition known as atherosclerosis. This significantly reduces the risk of serious cardiovascular events, including heart attacks, strokes, and the need for heart surgery. It is often prescribed for patients with coronary heart disease, diabetes, or other risk factors. Your doctor will typically recommend it alongside a heart-healthy diet and regular exercise.
The most frequently reported side effects of simvastatin include headache, constipation, nausea, and stomach pain. Some patients may also experience symptoms similar to the common cold, such as a stuffy nose or sore throat. While these are usually mild and tend to go away as the body adjusts to the medication, they should still be reported to a healthcare provider if they persist. More importantly, patients should watch for muscle pain or weakness, which can be a sign of a more serious condition. Although most people tolerate the drug well, regular monitoring by a physician is necessary. Always discuss any new or worsening symptoms with your medical team immediately.
Moderate alcohol consumption is generally considered safe for most people taking simvastatin, but caution is advised. Because both simvastatin and alcohol are processed by the liver, drinking excessively can increase the risk of liver damage or worsen statin-related side effects. People with a history of liver disease or those who are heavy drinkers should be especially careful and discuss their habits with their doctor. Binge drinking should be avoided entirely, as it can lead to a sudden increase in liver enzymes. Your healthcare provider may perform regular liver function tests to ensure the medication is not causing harm. If you experience yellowing of the skin or eyes, or dark urine, seek medical help immediately.
Simvastatin is generally not recommended during pregnancy and was traditionally contraindicated (Category X) because cholesterol is essential for the healthy development of a fetus. Recent FDA updates allow for some flexibility in high-risk cases, but for the vast majority of women, the drug should be stopped before trying to conceive or as soon as pregnancy is confirmed. There is a theoretical risk of birth defects if the fetus is exposed to statins during critical periods of development. Breastfeeding is also discouraged while taking this medication, as it is unknown if the drug passes into breast milk and how it might affect a nursing infant. Always consult your obstetrician and cardiologist to manage your cholesterol safely during pregnancy.
Simvastatin begins to lower cholesterol levels within about two weeks of starting the medication. However, it usually takes four to six weeks of consistent daily use to reach the maximum cholesterol-lowering effect. Your doctor will likely schedule a follow-up blood test (a lipid panel) after this initial period to see how well the drug is working and whether the dose needs adjustment. It is important to remember that simvastatin does not 'cure' high cholesterol; it manages it. Therefore, the medication must be taken long-term to maintain the benefits and continue protecting your cardiovascular system. Even if you feel fine, you should not stop taking the drug without your doctor's approval.
While stopping simvastatin suddenly does not cause a 'withdrawal' effect like some other medications, it will cause your cholesterol levels to rise back to their original levels within a few weeks. This increase in LDL cholesterol can raise your risk of heart attack or stroke, especially if you have existing heart disease. You should never stop taking simvastatin without first consulting your healthcare provider. If you are experiencing side effects that make you want to stop, your doctor may be able to adjust your dose or switch you to a different type of statin that you tolerate better. Consistency is key to the long-term prevention of cardiovascular complications.
If you miss a dose of simvastatin, take it as soon as you remember. If it is almost time for your next dose (for example, if you remember the next morning), skip the missed dose and take your next one at the usual time in the evening. Do not take two doses at once to make up for a missed one, as this can increase your risk of muscle toxicity and other side effects. To help you remember, try taking your medication at the same time every evening, perhaps right before bed or after dinner. Using a pill organizer or setting a daily alarm on your phone can also be very helpful in maintaining a consistent schedule.
Weight gain is not a commonly reported side effect of simvastatin in clinical trials. However, some studies have suggested that statin users might consume more calories because they feel 'protected' by the medication, which could lead to gradual weight gain over time. Additionally, there is a small risk of developing new-onset diabetes or increased blood sugar levels while on statins, which can sometimes be associated with weight changes. If you notice significant or rapid weight gain, it is more likely related to diet, lifestyle, or another underlying medical condition rather than the simvastatin itself. Maintaining a balanced diet and regular physical activity remains essential while taking this medication.
Simvastatin has many potential drug interactions, some of which can be very serious. It is particularly dangerous to take simvastatin with strong 'CYP3A4 inhibitors' like certain antifungals (ketoconazole), antibiotics (clarithromycin), or HIV medications, as these can cause the levels of simvastatin to skyrocket and lead to muscle breakdown. Other drugs, like certain blood pressure or heart rhythm medications (amlodipine, amiodarone), require your doctor to limit your simvastatin dose to 10 mg or 20 mg. Always provide your healthcare provider and pharmacist with a complete list of all prescriptions, over-the-counter drugs, and herbal supplements (like St. John's Wort) you are taking to avoid dangerous interactions.
Yes, simvastatin is widely available as a generic medication and is generally very affordable. The brand name version, Zocor, is also still available but is much more expensive. Generic simvastatin is required by the FDA to have the same active ingredient, strength, dosage form, and route of administration as the brand-name drug, meaning it is just as effective and safe. Most insurance plans prefer the generic version. Whether you take the brand or the generic, the clinical effects and the precautions you must take remain the same. Check with your pharmacist to ensure you are receiving the most cost-effective version of your prescription.